 Connection
Matthew Witkowski to T-Lymphocytes
This is a "connection" page, showing publications Matthew Witkowski has written about T-Lymphocytes.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.386 |
|
|
|
-
Ma C, Wang H, Liu L, Chen R, Mukherjee N, Tong J, Kazmi S, Fang X, Witkowski MT, Aifantis I, Ghassemi S, Chen W. Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia. Nat Biomed Eng. 2025 Dec; 9(12):2098-2114.
Score: 0.125
-
Witkowski MT, Kousteni S, Aifantis I. Mapping and targeting of the leukemic microenvironment. J Exp Med. 2020 02 03; 217(2).
Score: 0.086
-
Witkowski MT, Lasry A, Carroll WL, Aifantis I. Immune-Based Therapies in Acute Leukemia. Trends Cancer. 2019 10; 5(10):604-618.
Score: 0.083
-
Lee EF, Grabow S, Chappaz S, Dewson G, Hockings C, Kluck RM, Debrincat MA, Gray DH, Witkowski MT, Evangelista M, Pettikiriarachchi A, Bouillet P, Lane RM, Czabotar PE, Colman PM, Smith BJ, Kile BT, Fairlie WD. Physiological restraint of Bak by Bcl-xL is essential for cell survival. Genes Dev. 2016 05 15; 30(10):1240-50.
Score: 0.066
-
Liu L, Ma C, Zhang Z, Witkowski MT, Aifantis I, Ghassemi S, Chen W. Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse. J Immunother Cancer. 2022 12; 10(12).
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|